Featured Press Releases

ImmunityBio Announces FDA Approval of ANKTIVA®,

ImmunityBio Announces FDA Approval of ANKTIVA®,

Peer-Reviewed Study in Obesity Pillars Further Substantiates Cardiovascular Safety Profile of CONTRAVE®/MYSIMBA, according to Currax Pharmaceuticals

Peer-Reviewed Study in Obesity Pillars Further Substantiates Cardiovascular Safety Profile of CONTRAVE®/MYSIMBA, according to Currax Pharmaceuticals

  • 11 Mar 2025

Currax Pharmaceuticals LLC a specialty pharmaceutical company and manufacturer of the #1 branded...

Qualia NAD+ Shown In Preliminary Clinical Study To Increase NAD+ By 85%

Qualia NAD+ Shown In Preliminary Clinical Study To Increase NAD+ By 85%

Gvoke VialDx™ (glucagon injection) Launched by American Regent

Gvoke VialDx™ (glucagon injection) Launched by American Regent

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ Subcutaneous Maintenance Dose for Early Alzheimer

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ Subcutaneous Maintenance Dose for Early Alzheimer's Treatment

Fresenius Kabi’s biosimilars Conexxence® and Bomyntra® (denosumab-bnht) receive interchangeable designation from the FDA

Fresenius Kabi’s biosimilars Conexxence® and Bomyntra® (denosumab-bnht) receive interchangeable designation from the FDA

Eli Lilly’s Foundayo™: The Newest GLP-1 Innovation Offered by Ro

Eli Lilly’s Foundayo™: The Newest GLP-1 Innovation Offered by Ro

  • Ro
  • 09 Apr 2026
Approval and Launch of Nintedanib Capsules

Approval and Launch of Nintedanib Capsules

  • Dexcel Pharma USA
  • 09 Apr 2026
When Every Beat Matters, BD Helps Clinicians Gain Continuous, Noninvasive Blood Pressure Insight to Eliminate Blind Spots

When Every Beat Matters, BD Helps Clinicians Gain Continuous, Noninvasive Blood Pressure Insight to Eliminate Blind Spots

  • BD
  • 07 Apr 2026
Dr. Amit Singal Appointed as Chief Medical Officer by Curve Biosciences

Dr. Amit Singal Appointed as Chief Medical Officer by Curve Biosciences

  • Curve Biosciences
  • 07 Apr 2026
MEDIPEEL Gains Momentum in the K-Pharmacy Channel in Korea.

MEDIPEEL Gains Momentum in the K-Pharmacy Channel in Korea.

  • MEDIPEEL
  • 06 Apr 2026
Epia Neuro Launches Intent-Driven Neural Technology to Restore Function After Stroke and Address Cognitive Decline

Epia Neuro Launches Intent-Driven Neural Technology to Restore Function After Stroke and Address Cognitive Decline

  • Epia Neuro
  • 06 Apr 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
April   2026
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30      

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.